Payment overview · 2025
General Payments
$668.70
31 reported records · 16 companies
Healthcare provider profile · identity verified
Jeffrey D Rettig, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GROESBECK, TX · NPI 1528005550
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D Rettig, D.O. received $668.70 in general payments during 2025 across 31 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.42 | 14.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.19 | 10.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.74 | 10.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.91 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.53 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.29 | 7.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.70 | 7.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.70 | 6.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.11 | 5.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.44 | 3.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.11 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.92 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.49 | 2.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $16.82 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.73 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.60 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $668.70 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $145.12 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $68.74 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.91 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $38.84 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
422 | 68 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1179 | 265 |
| Levothyroxine Sodium | Levothyroxine Sodium | 929 | 170 |
| Gabapentin | Gabapentin | 768 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 720 | 188 |
| Furosemide | Furosemide | 658 | 111 |
| Lisinopril | Lisinopril | 524 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 505 | 140 |
| Potassium Chloride | Potassium Chloride | 456 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 123 |
| Eliquis | Apixaban | 422 | 68 |
| Carvedilol | Carvedilol | 407 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 355 | 36 |
| Donepezil Hcl | Donepezil Hcl | 335 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 321 | 70 |
| Montelukast Sodium | Montelukast Sodium | 320 | 87 |
| Metformin Hcl Er | Metformin Hcl | 316 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 313 | 82 |
| Trazodone Hcl | Trazodone Hcl | 296 | 72 |
| Mirtazapine | Mirtazapine | 278 | 70 |
| Omeprazole | Omeprazole | 271 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 70 |
| Losartan Potassium | Losartan Potassium | 263 | 87 |
| Ezetimibe | Ezetimibe | 252 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 248 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 63 |
| Allopurinol | Allopurinol | 247 | 60 |
| Metformin Hcl | Metformin Hcl | 218 | 59 |
| Sertraline Hcl | Sertraline Hcl | 215 | 51 |
| Tramadol Hcl | Tramadol Hcl | 215 | 74 |
| Alendronate Sodium | Alendronate Sodium | 214 | 53 |
| Simvastatin | Simvastatin | 209 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 57 |
| Levetiracetam | Levetiracetam | 184 | 24 |
| Divalproex Sodium | Divalproex Sodium | 182 | 36 |
| Ozempic | Semaglutide | 181 | 36 |
| Myrbetriq | Mirabegron | 178 | 28 |
| Buspirone Hcl | Buspirone Hcl | 165 | 33 |
| Glimepiride | Glimepiride | 161 | 49 |
| Memantine Hcl | Memantine Hcl | 151 | 36 |
| Meloxicam | Meloxicam | 150 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 38 |
| Jardiance | Empagliflozin | 148 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 142 | 24 |
| Prednisone | Prednisone | 142 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 21 |
| Glipizide | Glipizide | 138 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 34 |
| Spironolactone | Spironolactone | 128 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 116 | 33 |
| Famotidine | Famotidine | 115 | 34 |
| Risperidone | Risperidone | 110 | 19 |
| Pregabalin | Pregabalin | 108 | 33 |
| Aripiprazole | Aripiprazole | 107 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 107 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 20 |
| Warfarin Sodium | Warfarin Sodium | 90 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 49 |
| Farxiga | Dapagliflozin Propanediol | 83 | 18 |
| Valsartan | Valsartan | 79 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 40 |
| Divalproex Sodium Er | Divalproex Sodium | 76 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 19 |
| Finasteride | Finasteride | 75 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 18 |
| Januvia | Sitagliptin Phosphate | 72 | suppressed |
| Ramipril | Ramipril | 70 | 21 |
| Celecoxib | Celecoxib | 68 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 19 |
| Cefuroxime | Cefuroxime Axetil | 65 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 19 |
| Methylprednisolone | Methylprednisolone | 64 | 55 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 42 |
| Fenofibrate | Fenofibrate | 63 | 12 |
| Glipizide Er | Glipizide | 59 | 17 |
| Torsemide | Torsemide | 58 | 14 |
| Bupropion Xl | Bupropion Hcl | 57 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 16 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Gemtesa | Vibegron | 56 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 17 |
| Alprazolam | Alprazolam | 55 | 20 |
| Nifedipine Er | Nifedipine | 55 | 11 |
| Ondansetron Odt | Ondansetron | 55 | 32 |
| Benazepril Hcl | Benazepril Hcl | 54 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Cephalexin | Cephalexin | 54 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 36 |
| Levofloxacin | Levofloxacin | 54 | 31 |
| Azithromycin | Azithromycin | 53 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | 16 |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Digoxin | Digoxin | 46 | suppressed |
| Naproxen | Naproxen | 46 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 12 |
| Lorazepam | Lorazepam | 39 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 28 |
| Nystatin | Nystatin | 38 | 21 |
| Nystop | Nystatin | 38 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Fluconazole | Fluconazole | 37 | 27 |
| Felodipine Er | Felodipine | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 26 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 11 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 34 | 27 |
| Leflunomide | Leflunomide | 34 | suppressed |
| Haloperidol | Haloperidol | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Budesonide | Budesonide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | 16 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $668.70 · 31 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, Auvelity, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, COMIRNATY, CREON, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, VAQTA, VAXNEUVANCE, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error